The use of the global CB1 antagonist Rimonabant in the treatment of obesity has been hampered by its adverse effects on the central nervous system (CNS) resulting in adverse psychological side effects [7]. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.